NCT03006159View on ClinicalTrials.gov

A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Type 2 Diabetic Patients
Interventions
DRUG

SHR0534

DRUG

Placebo

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03006159 - A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter